This 1-hour webinar explores how sensor-based digital health technologies (DHTs) can be used to collect clinically meaningful information about the health and behavior of patients with heart failure (HF).Experts in clinical research share their experience remotely obtaining and analyzing real-world data from sensor-based DHT to study and develop treatments for HF ...
More than 90% of rare diseases do not have any treatment, representing a substantial unmet need for patients. The development of new therapies is especially challenging given the poor understanding of rare diseases in general and the lack of established endpoints for clinical trials ...
Digital transformation in healthcare and clinical research has been slower to progress than in other economic sectors, such as consumer goods and communications. To ensure the rights and safety of vulnerable populations, digital health technologies (DHTs) used in clinical research and care demand a high level of compliance and validation. To accelerate digital transformation in healthcare ...
Clinical trial sponsors are increasingly leveraging digital health technologies (DHTs) to capture real-world, patient-centric outcome measures in their studies. Although these tools provide near endless opportunities to improve study efficiencies and unlock new participant insights, many study teams struggle with the operational complexities of deploying DHTs into large-scale, global clinical ...
Technology-enabled decentralized clinical trials (DCTs) are transforming drug development by lowering participation barriers and burdens while expanding the opportunities to collect data. However, the operational complexities of managing multiple remote technologies can be overwhelming.
In 2018, ActiGraph released the CentrePoint® Insight Watch (CPIW), a fit-for-purpose wearable designed to collect continuous, real-world physical activity data - passively, comfortably, and easily - without the need for frequent battery charging. In April of this year, we will release v. 2.0 of that product, which includes a scratch resistant glass ...
Wearable sensors and connected digital technologies have the potential to revolutionize how we study, treat, and manage cancer research and care. The collection of continuous, real-world physiological and behavioral signals provides an opportunity for oncology researchers to develop a new class of objective and sensitive endpoints that are clinically meaningful ...
As the digital transformation of clinical research and the adoption of decentralized clinical trials continue to gain momentum, sponsors are increasingly using wearable motion-sensing technologies to capture real-world digital biomarker data. In exchange for the valuable insights into treatment efficacy and quality of life they provide, successful wearable technology deployments ...
Wearable technologies deliver valuable clinical insights, and they also introduce new layers of complexity and risk for study design and clinical operations teams. Selecting a wearable technology that is well-aligned with your study population, endpoints of interest, and trial design is the first step in optimizing the quality of your ...
ActiGraph CEO, Jeremy Wyatt joins a panel of experts from HumanFirst, Atlantic Council, and Samsung NeuroLogica take a deep dive and answer key questions into the evaluation of digital biomarkers and digital measurements during the discussion "What Level of Evidence is Needed to Evaluate Biomarkers and Measurements?”
CNS Summit 2020 Spotlight Session, "Developing an Effective Data Asset Strategy for Wearable Devices in Clinical Trials," moderated by Jeremy Wyatt, ActiGraph CEO, and featuring an all-star panel of thought leaders from Bristol Myers Squibb, Takeda, Roche, and the University of California San Diego. Panelists discuss a framework for understanding the ...
Mobile in Clinical Trials virtual panel discussion, “Traversing the Regulatory Road to Qualifying a Digital Endpoint; Twists and Turns.” ActiGraph CEO, Jeremy Wyatt, joined a panel of thought leaders from Pfizer, Boehringer Ingelheim, Biogen, and ICON to discuss a framework for the qualification of novel digital endpoints and the regulatory ...
The COVID-19 pandemic has created widespread disruptions to nearly every aspect of society. As many universities pivot to virtual instruction and existing studies with traditional workflows grind to a halt amid concerns for the safety of participants and personnel, the impacts of slowing academic research will likely be felt for ...
The promise of wearables has always been clear. It’s time to deliver on that promise. COVID-19 and the imminent rise of 5G networks are an accelerant, deepening our commitment to the use of wearables and sensors to capture better digital endpoints remotely. But in our collective rush to run ...
snapIoT, Covance, and ActiGraph discuss expectations of wearables, achieving successful mHealth integrations, and the industry’s best practices in the rapid deployment of decentralized clinical trials. Topics of discussion: Develop realistic expectations when selecting wearable devices for today’s Decentralized Trials Compare lessons learned from the ‘trendsetters’ in the rapid-deployment ...
Today, less than 15% of clinical trials capture data from mobile sensors. In many cases these data are used to derive exploratory endpoints, but in some cases they are being used for primary or secondary endpoints. Mobile sensors can be used to measure aspects of health and function which are difficult ...
In this webinar, ActiGraph’s Jeremy Wyatt is joined by Job Godino, PhD, to discuss key challenges and opportunities around the validation of digital clinical endpoints captured with wearable sensors, addressing both historic data interpretation methods and the ways in which these may change in the future. This 45 minute webinar ...
